Inhalation Sciences (ISAB) has announced that a “noted global pharma company” has placed an order worth €75,000 for a contract research project utilizing ISAB’s DissolvIt system. The DissolvIt module is used to simulate dissolution and absorption of dry powder formulations in the lung and generates data including Cmax and Tmax curves.
ISAB CEO Manoush Masarrat commented, “This new order from a returning client underlines the benefits DissolvIt gives inhaled drug developers. The voluminous, precise data DissolvIt deliver are, quite simply, leading. It’s a world-class solution. This new order confirms it once again.”
Masarrat added, “Our CRO services are crucial for us and our clients. They build long-term relationships and collaborations, demonstrating to new customers the outstanding capabilities of our technology. With today’s travel restrictions during the ongoing COVID-19 pandemic, ISAB’s CRO services have continued to be a high-value way to keep providing our customers with the leading data they need, and that today’s situation requires.”
The company’s PreciseInhale dosing system is used to deposit particles for analysis by DissolvIt. In May 2019, Inhalation Sciences announced that it intended to validate the PreciseInhale for clinical use.
Read the Inhalation Sciences press release.
